Berthold BIVIGOU MBOUMBA

Dr. Berthold BIVIGOU MBOUMBA


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2017 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
PDF file
SMSheila Makiala-Mandanda
Sheila Makiala-Mandanda
FGFrédéric Le Gal
Frédéric Le Gal
NNNadine Ngwaka-Matsung
Nadine Ngwaka-Matsung
SASteve Ahuka-Mundeke
Steve Ahuka-Mundeke
RORichard Onanga
Richard Onanga
PBPierre Becquart
Pierre Becquart
The majority of patients with acute febrile jaundice (>95%) identified through a yellow fever surveillance program in the Democratic Republic of Congo (DRC) test negative for antibodies against yellow fever virus. However, no etiological investigation has ever been carried out on these patients. Here, we tested for hepatitis A (HAV), hepatitis B (HBV), hepatitis C (HCV), hepatitis D (HDV), and hepatitis E (HEV) viruses, all of which can cause acute febrile jaundice, in patients included in the yellow fever surveillance program in the DRC. On a total of 498 serum samples collected from suspected cases of yellow fever from January 2003 to January 2012, enzyme-linked immunosorbent assay (ELISA) techniques were used to screen for antibodies against HAV (IgM) and HEV (IgM) and for antigens and antibodies against HBV (HBsAg and anti-hepatitis B core protein [HBc] IgM, respectively), HCV, and HDV. Viral loads and genotypes were determined for HBV and HVD. Viral hepatitis serological markers were diagnosed in 218 (43.7%) patients. The seroprevalences were 16.7% for HAV, 24.6% for HBV, 2.3% for HCV, and 10.4% for HEV, and 26.1% of HBV-positive patients were also infected with HDV. Median viral loads were 4.19 × 10 5 IU/ml for HBV (range, 769 to 9.82 × 10 9 IU/ml) and 1.4 × 10 6 IU/ml for HDV (range, 3.1 × 10 2 to 2.9 × 10 8 IU/ml). Genotypes A, E, and D of HBV and genotype 1 of HDV were detected. These high hepatitis prevalence rates highlight the necessity to include screening for hepatitis viruses in the yellow fever surveillance program in the DRC.

9 January 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Berthold BIVIGOU MBOUMBABerthold BIVIGOU MBOUMBA
Berthold BIVIGOU MBOUMBA
MAMarie Amougou-Atsama
Marie Amougou-Atsama
SZSamira Zoa-Assoumou
Samira Zoa-Assoumou
HKHervé M'Boyis Kamdem
Hervé M'Boyis Kamdem
GNGuy Francis Nzengui-Nzengui
Guy Francis Nzengui-Nzengui
SFSandrine Francois
Sandrine Francois
In Gabon, a central African country, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) are endemic. In a recent study, conducted in a semi-urban area (Franceville, Gabon), HBV infection was found to be more prevalent among HIV infected individuals. This study aims to investigate the prevalence and genetic diversity of hepatitis B virus infection among HIV infected individuals, predominantly under antiretroviral therapy, living in fully urbanized area: Libreville, capital of Gabon. Serological and molecular tests were performed to detect HBV infection among patients living with HIV/AIDS (PLHA). We used Monolisa HBsAg ULTRA, Anti-HBc Plus and Anti-HBs Plus EIA kits for serological analyses. HBV DNA viral load (HBV DNA VL) was determined by real time PCR and molecular characterization of HBV strains was performed by sequencing and phylogenetic analysis of partial HBV surface and core genes. At all, 70.2% of patients were under antiretroviral therapy. The prevalence of HBsAg was 8.8% (43/487). Detectable HBV DNA was found in 69.7% (30/43) of HBsAg positive patients and in 17.5% (24/137) HBsAg negative patients. HBV DNA VL was significantly higher among patient with CD4 cell counts less than 200 cells/mm3 than those with CD4 cell counts greater than 500 cells/mm3 (p = 0.008). We confirmed the presence of HBV sub-genotypes QS-A3 (40%), and A4 (20%) and HBV-E genotype (40%). The percentage of resistance to Lamivudine was high (40%) and varied according to the M204V/I motif. Occult hepatitis B infection (OBI) was found in patients with isolated HBcAb and among patients who had completed their HBsAg seroconversion. We detected HBV DNA for one patient without any HBV serological marker. This study provides a new landmark for the comprehension of HBV infection in PLHA in urban areas. OBI enhances HBV DNA prevalence and should be investigated in all HBsAg negative individuals.

1 July 2017 in Medecine Et Sante Tropicales
Verified
Journal Article
Closed access
Berthold BIVIGOU MBOUMBABerthold BIVIGOU MBOUMBA
Berthold BIVIGOU MBOUMBA
FRF. Rouet
F. Rouet
Augustin MOUINGA ONDEMEAugustin MOUINGA ONDEME
Augustin MOUINGA ONDEME
LDL. Deleplancque
L. Deleplancque
JSJ. Sica
J. Sica
SFSandrine Francois
Sandrine Francois
Access to antiretrovirals has increased the life expectancy of patients living with HIV. However, HIV-viral hepatitis coinfections in countries endemic for these infections make management more difficult. To determine the extent of these coinfections in Gabon, we investigated markers of hepatitis B, C, and E viruses in 762 adults infected with HIV-1 by ELISA. We used real-time PCR to quantify plasma HBV DNA (HBV VL) and amplified HCV and HEV RNA by nested RT-PCR and PCR.The seroprevalence of chronic hepatitis B infection was 9.3 %. Among patients with isolated HBcAc profiles, the prevalence of occult hepatitis B infection was 26.7 %, for a real prevalence (detectable CV-HBV) of 17.3 % of the total population. HCV seroprevalence was 8.8 %. Of the 67 HIV-positive patients, 76.1 % had replicative profiles (detectable HCV RNA), that is, 6.7 % of the total population. For hepatitis E, seroprevalence was 3.5 %. No case of chronic HEV infection was found. In conclusion, this study highlights a high rate of HIV-Hepatitis B, C and E coinfections in Gabon. In addition, we show the interest of looking for chronic infections (replicative profiles) in HIV-infected patients in Gabon. The establishment of technical platforms for this type of research, accessible to middle-income countries, is necessary.

12 December 2018
Verified
Book Chapter
Open access
PDF file
Berthold BIVIGOU MBOUMBABerthold BIVIGOU MBOUMBA
Berthold BIVIGOU MBOUMBA
The global epidemics of hepatitis B and HIV have led to a new understanding of the complex interactions between these two viruses. Due to similar patterns of contamination, the high prevalence of HBV infection among the 33 million people living with HIV (PLHIV) across the world is about 10%. In highly endemic areas such as sub-Saharan Africa, this prevalence can be as high as 15% and leads us systematically to seek HIV/HBV co-infection. According to WHO, nearly 240 million people are chronically infected with HBV worldwide. Of these, 4 million are co-infected with HIV. Overall, co-infection rates range from 5 to 14% in areas of low prevalence of HBV infection and 5–73% in areas of high prevalence for HBV infection. Studies have revealed the complexity of the infection relationship between HIV and HBV. This complex relationship is thought to be responsible for greater morbidity and mortality of hepatic origin in co-infected patients than in mono-infected individuals. This chapter will highlight the following main points: Concomitant negative impact of HIV and HBV on their natural histories Implication of concomitant negative impact on the overall management of HIV-HBV coinfection Treatment and management.

2 August 2020 in American Journal of Case Reports
Verified
Journal Article
Closed access
PDF file
GMGuignali Laurette Mangouka
Guignali Laurette Mangouka
BIBerthe Amélie Iroungou
Berthe Amélie Iroungou
Berthold BIVIGOU MBOUMBABerthold BIVIGOU MBOUMBA
Berthold BIVIGOU MBOUMBA
DNDavy Ngabou
Davy Ngabou
EMEl Medhi Badidi Moulay
El Medhi Badidi Moulay
JNJean Raymond Nzenze
Jean Raymond Nzenze
BACKGROUND:Takayasu disease is a rare disease affecting large vessels, particularly the aorta and its main branches. The affected arteries become partially occluded. The disease is more frequent in women under 40 years of age, with a ratio of women to men of 8: 1. CASE REPORT:We report the case of a 39-year-old woman who was admitted to the medical ward at the Military Hospital in Gabon. She presented with multiple aneurysms, arterial stenosis, and a positive tuberculin skin test and was diagnosed with Takayasu disease associated with latent tuberculosis infection. This rare case is the first to be reported in Gabon, with a delay in diagnosis of approximately 7 months. CONCLUSIONS:This is the first case of Takayasu arteritis that has been described in Gabon and has generated medical interest beyond the country regarding the diagnostic, therapeutic, and prognostic approach.

7 May 2026 in Pathogens
Verified
Journal Article
Open access
PDF file
Berthold BIVIGOU MBOUMBABerthold BIVIGOU MBOUMBA
Berthold BIVIGOU MBOUMBA
PBPamela Moussavou Boundzanga
Pamela Moussavou Boundzanga
FAFalone L. Akombi
Falone L. Akombi
CZCarine Eyi Zang
Carine Eyi Zang
ABAurore F. Bouassa-Bouassa
Aurore F. Bouassa-Bouassa
SASimon Ategbo
Simon Ategbo
Background: Children, adolescents and young adults living with HIV represent a vulnerable population. Achieving viral suppression in this population remains a major challenge in sub-Saharan Africa. Methods: We conducted a cross-sectional study among HIV-positive individuals aged 0–24 years in Gabon. Data were collected, including viral load (VL), CD4 counts, and immunosuppression levels. Viral suppression was defined as VL < 1000 copies/mL. Statistical comparisons across age groups and immunosuppression categories were performed. Results: Of the 130 (100%) participants included, 59 (45.4%) were males and 71 (54.6%) females. Overall, 72 (55.4%) achieved viral suppression, while 58 (44.6%) remained uncontrolled. Viral suppression increased with age (23.8% (5/21) in 0–7 years; 29.2% (14/48) in 8–15 year and 42.6% (26/61) in 16–24 years), yet uncontrolled VL were predominant across all groups. Median VL values were low but showed wide interquartile ranges, indicating heterogeneity in viral control. Mean CD4 counts declined significantly with age (780 in 0–8 years vs. 470 in 16–24 years; p = 0.001). Immunosuppression levels correlated inversely with virological control (p < 0.001). Conclusions: Despite moderate overall viral suppression, nearly half of adolescents and young adults failed to achieve virological control. The decline in CD4 counts with age highlights increased vulnerability in this population.